We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radiofrequency Ablation Reduces Bone Cancer Pain

By HospiMedica staff writers
Posted on 12 Dec 2002
Radiofrequency ablation (RFA) can reduce pain and improve quality of life in most patients with metastatic bone cancer, according to a study presented at the annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL (USA).

Guided by computed tomography (CT) or ultrasound, RFA transmits electrical energy through a very small needle inserted through the skin directly into carefully targeted tissue around a tumor. More...
The high-frequency currents heat and destroy a large part of the tumor. Although RFA has shown success in treating other types of cancer, this study shows it is also effective for cancer that has spread to the bone. The US Food and Drug Administration (FDA) has cleared RFA for treatment of bone cancer pain.

Patients with cancer spread throughout the body cannot be treated with RFA. Thus, the patients in the multicenter study had one or two painful lesions, and chemotherapy had not be palliative, leaving patients to rely on narcotic pain relievers. Of the 62 patients who took part in the study, about 50 (81%) attained a high degree of pain relief, while 28 (45%) had complete elimination of pain at some point during the six-month follow-up. Many had a minimal amount of pain even at the end of life.

"Through RFA treatment, we have been able to reduce fairly severe pain down to the point where pain is not controlling our patients' every thought. They have a good quality of life,” said Dr. Matthew R. Callstrom, M.D., Ph.D., assistant professor of radiology at the Mayo Clinic (Rochester, MN, USA), one of the centers participating in the study.




Related Links:
Mayo Clinic

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.